# Prelude Therapeutics Inc: filings

PRLD · Nasdaq · CIK 1678660 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prld.md) · [Financials](/companies/prld/financials.md) · [Filings](/companies/prld/filings.md) · [Insiders](/companies/prld/insiders.md)

## Reports and events: 115 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 161, 8-K 70, 3 23, 10-Q 18, CORRESP 12, SC 13G/A 10, S-8 7, 10-K 6, DEF 14A 6, DEFA14A 6, EFFECT 6, UPLOAD 6, 424B5 5, SC 13D/A 5, ARS 4, D 4, S-3 4, SC 13G 4, SCHEDULE 13G/A 4, SCHEDULE 13D/A 3, 424B4 2, DRS 2, PRE 14A 2, S-1 2, S-1/A 2, SC 13D 2, SCHEDULE 13G 2, 4/A 1, 8-A12B 1, 8-K/A 1, CERT 1, D/A 1, DRS/A 1, DRSLTR 1, FWP 1, S-1MEF 1, S-3/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-10 | 07:29 ET | [8-K](/filings/0001193125-26-387232.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-387232 |
| 2026-08-11 | 08:05 ET | [10-Q](/filings/0001193125-26-343475.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343475 |
| 2026-08-11 | 08:00 ET | [8-K](/filings/0001193125-26-343469.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343469 |
| 2026-06-10 | 16:11 ET | [8-K](/filings/0001193125-26-265835.md) | 5.07 Shareholder vote results | 0001193125-26-265835 |
| 2026-05-12 | 07:19 ET | [10-Q](/filings/0001193125-26-218173.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218173 |
| 2026-05-12 | 07:11 ET | [8-K](/filings/0001193125-26-218162.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-218162 |
| 2026-04-29 | 16:08 ET | [DEF 14A](/filings/0001193125-26-191532.md) | Proxy statement, period 2026-06-09 | 0001193125-26-191532 |
| 2026-04-23 | 20:42 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000463.md) | Ownership report, active investor, amended | 0000947871-26-000463 |
| 2026-04-22 | 16:22 ET | [SCHEDULE 13D/A](/filings/0001104659-26-046848.md) | Ownership report, active investor, amended | 0001104659-26-046848 |
| 2026-04-21 | 19:04 ET | [8-K](/filings/0001193125-26-164510.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-164510 |
| 2026-04-20 | 06:16 ET | [8-K](/filings/0001193125-26-162620.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-162620 |
| 2026-04-15 | 07:41 ET | [8-K](/filings/0001193125-26-155978.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-155978 |
| 2026-03-12 | 16:18 ET | [8-K](/filings/0001193125-26-104204.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-104204 |
| 2026-03-10 | 08:24 ET | [10-K](/filings/0001193125-26-099428.md) | Annual report, period 2025-12-31 | 0001193125-26-099428 |
| 2026-03-10 | 08:17 ET | [8-K](/filings/0001193125-26-099424.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-099424 |
| 2026-02-03 | 09:11 ET | [8-K](/filings/0001193125-26-034564.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-034564 |
| 2026-01-09 | 07:30 ET | [8-K](/filings/0001193125-26-008280.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-008280 |
| 2025-11-12 | 07:15 ET | [10-Q](/filings/0001193125-25-275887.md) | Quarterly report, period 2025-09-30 | 0001193125-25-275887 |
| 2025-11-12 | 07:07 ET | [8-K](/filings/0001193125-25-275871.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-275871 |
| 2025-11-04 | 08:53 ET | [8-K](/filings/0000929638-25-004115.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000929638-25-004115 |
| 2025-10-17 | 07:40 ET | [8-K](/filings/0001193125-25-241968.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001193125-25-241968 |
| 2025-09-19 | 07:41 ET | [8-K](/filings/0001193125-25-208187.md) | 8.01 Other events | 0001193125-25-208187 |
| 2025-08-14 | 07:23 ET | [10-Q](/filings/0000950170-25-108417.md) | Quarterly report, period 2025-06-30 | 0000950170-25-108417 |
| 2025-08-14 | 07:07 ET | [8-K](/filings/0000950170-25-108413.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-108413 |
| 2025-06-13 | 17:21 ET | [SCHEDULE 13D/A](/filings/0001104659-25-059474.md) | Ownership report, active investor, amended | 0001104659-25-059474 |
| 2025-06-13 | 16:10 ET | [8-K](/filings/0000950170-25-086170.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000950170-25-086170 |
| 2025-05-06 | 16:45 ET | [10-Q](/filings/0000950170-25-064566.md) | Quarterly report, period 2025-03-31 | 0000950170-25-064566 |
| 2025-05-06 | 16:30 ET | [8-K](/filings/0000950170-25-064531.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-064531 |
| 2025-04-29 | 07:00 ET | [DEF 14A](/filings/0000950170-25-059549.md) | Proxy statement, period 2025-06-12 | 0000950170-25-059549 |
| 2025-04-25 | 16:30 ET | [8-K](/filings/0000950170-25-058776.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-058776 |
| 2025-03-28 | 16:30 ET | [8-K](/filings/0000950170-25-046839.md) | 3.01 Delisting notice | 0000950170-25-046839 |
| 2025-03-10 | 07:50 ET | [10-K](/filings/0000950170-25-035921.md) | Annual report, period 2024-12-31 | 0000950170-25-035921 |
| 2025-03-10 | 07:40 ET | [8-K](/filings/0000950170-25-035917.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-035917 |
| 2025-02-05 | 16:28 ET | [8-K](/filings/0000950170-25-014543.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-014543 |
| 2024-12-11 | 07:45 ET | [8-K](/filings/0000950170-24-135212.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-135212 |
| 2024-11-06 | 16:27 ET | [10-Q](/filings/0000950170-24-122377.md) | Quarterly report, period 2024-09-30 | 0000950170-24-122377 |
| 2024-11-06 | 16:15 ET | [8-K](/filings/0000950170-24-122337.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-122337 |
| 2024-10-24 | 07:40 ET | [8-K](/filings/0000950170-24-116853.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-116853 |
| 2024-09-13 | 16:15 ET | [8-K](/filings/0000950170-24-106362.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-106362 |
| 2024-09-09 | 09:02 ET | [8-K](/filings/0000950170-24-104575.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-104575 |
| 2024-08-12 | 07:20 ET | [10-Q](/filings/0000950170-24-095065.md) | Quarterly report, period 2024-06-30 | 0000950170-24-095065 |
| 2024-08-12 | 07:10 ET | [8-K](/filings/0000950170-24-095059.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-095059 |
| 2024-06-18 | 16:06 ET | [8-K](/filings/0000950170-24-074846.md) | 5.07 Shareholder vote results | 0000950170-24-074846 |
| 2024-06-12 | 06:55 ET | [8-K](/filings/0000950170-24-072249.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-072249 |
| 2024-05-16 | 16:09 ET | [8-K/A](/filings/0000950170-24-061079.md) | 5.02 Departure or appointment of officers or directors | 0000950170-24-061079 |
| 2024-05-07 | 07:20 ET | [10-Q](/filings/0000950170-24-053940.md) | Quarterly report, period 2024-03-31 | 0000950170-24-053940 |
| 2024-05-07 | 07:12 ET | [8-K](/filings/0000950170-24-053931.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-053931 |
| 2024-04-26 | 16:11 ET | [DEF 14A](/filings/0000950170-24-049126.md) | Proxy statement, period 2024-06-14 | 0000950170-24-049126 |
| 2024-04-10 | 16:05 ET | [8-K](/filings/0000950170-24-043347.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-043347 |
| 2024-02-15 | 17:22 ET | [10-K](/filings/0000950170-24-016016.md) | Annual report, period 2023-12-31 | 0000950170-24-016016 |

Page 1 of 3. [Older](/companies/prld/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.